全文获取类型
收费全文 | 794篇 |
免费 | 54篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 74篇 |
妇产科学 | 18篇 |
基础医学 | 77篇 |
口腔科学 | 16篇 |
临床医学 | 64篇 |
内科学 | 108篇 |
皮肤病学 | 7篇 |
神经病学 | 82篇 |
特种医学 | 90篇 |
外科学 | 75篇 |
综合类 | 32篇 |
预防医学 | 118篇 |
眼科学 | 2篇 |
药学 | 61篇 |
肿瘤学 | 30篇 |
出版年
2021年 | 9篇 |
2020年 | 4篇 |
2018年 | 7篇 |
2017年 | 4篇 |
2016年 | 19篇 |
2015年 | 11篇 |
2014年 | 29篇 |
2013年 | 25篇 |
2012年 | 23篇 |
2011年 | 28篇 |
2010年 | 26篇 |
2009年 | 22篇 |
2008年 | 34篇 |
2007年 | 35篇 |
2006年 | 35篇 |
2005年 | 31篇 |
2004年 | 31篇 |
2003年 | 18篇 |
2002年 | 14篇 |
2001年 | 15篇 |
2000年 | 13篇 |
1999年 | 25篇 |
1998年 | 29篇 |
1997年 | 24篇 |
1996年 | 25篇 |
1995年 | 25篇 |
1994年 | 14篇 |
1993年 | 10篇 |
1992年 | 17篇 |
1991年 | 10篇 |
1990年 | 13篇 |
1989年 | 21篇 |
1988年 | 21篇 |
1987年 | 15篇 |
1986年 | 21篇 |
1985年 | 31篇 |
1984年 | 14篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 9篇 |
1979年 | 5篇 |
1976年 | 11篇 |
1975年 | 3篇 |
1974年 | 5篇 |
1973年 | 6篇 |
1972年 | 13篇 |
1968年 | 4篇 |
1966年 | 5篇 |
1960年 | 3篇 |
排序方式: 共有861条查询结果,搜索用时 0 毫秒
861.
What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study
下载免费PDF全文
![点击此处可从《International journal of cancer. Journal international du cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rebecca Landy Peter Windridge Matthew S. Gillman Peter D. Sasieni 《International journal of cancer. Journal international du cancer》2018,142(4):709-718
Women vaccinated against HPV16/18 are approaching the age for cervical screening; however, an updated screening algorithm has not been agreed. We use a microsimulation model calibrated to real published data to determine the appropriate screening intensity for vaccinated women. Natural histories in the absence of vaccination were simulated for 300,000 women using 10,000 sets of transition probabilities. Vaccination with (i) 100% efficacy against HPV16/18, (ii) 15% cross‐protection, (iii) 22% cross‐protection, (iv) waning vaccine efficacy and (v) 100% efficacy against HPV16/18/31/33/45/52/58 was added, as were a range of screening scenarios appropriate to the UK. To benchmark cost‐benefits of screening for vaccinated women, we evaluated the proportion of cancers prevented per additional screen (incremental benefit) of current cytology and likely HPV screening scenarios in unvaccinated women. Slightly more cancers are prevented through vaccination with no screening (70.3%, 95% CR: 65.1–75.5) than realistic compliance to the current UK screening programme in the absence of vaccination (64.3%, 95% CR: 61.3–66.8). In unvaccinated women, when switching to HPV primary testing, there is no loss in effectiveness when doubling the screening interval. Benchmarking supports screening scenarios with incremental benefits of ≥2.0%, and rejects scenarios with incremental benefits ≤0.9%. In HPV16/18‐vaccinated women, the incremental benefit of offering a third lifetime screen was at most 3.3% (95% CR: 2.2–4.5), with an incremental benefit of 1.3% (?0.3–2.8) for a fourth screen. For HPV16/18/31/33/45/52/58‐vaccinated women, two lifetime screens are supported. It is important to know women's vaccination status; in these simulations, HPV16/18‐vaccinated women require three lifetime screens, HPV16/18/31/33/45/52/58‐vaccinated women require two lifetime screens, yet unvaccinated women require seven lifetime screens. 相似文献